不同剂量维生素C对危重症患者死亡率影响的荟萃分析
该荟萃分析检索静脉给予维生素C的危重症成人研究,共纳入1210例患者,主要终点为末次随访全因死亡率。静脉维生素C 3-10 g/d降低死亡率(OR 0.25;95%CI 0.14-0.46;p<0.001;I²=0.0%),而<3 g/d(OR 1.44;95%CI 0.79-2.61;p=0.234;I²=0.0%)和≥10 g/d(OR 1.12;95%CI 0.62-2.03;p=0.700;I²=0.0%)无效应。维生素C与血管活性药支持和机械通气时间缩短相关,但不影响入科24小时内液体需求或尿量,急性肾损伤例数、ICU或住院时间也未受影响。鉴于原始文献的局限性,作者认为需进一步研究以明确维生素C在危重症管理中的有效性。
要点
- 静脉维生素C 3-10 g/d与危重症成人死亡率降低相关:OR 0.25(95%CI 0.14-0.46;p<0.001;I²=0.0%)。
- 低剂量(<3 g/d)无死亡获益:OR 1.44(95%CI 0.79-2.61;p=0.234;I²=0.0%)。
- 高剂量(≥10 g/d)无死亡获益:OR 1.12(95%CI 0.62-2.03;p=0.700;I²=0.0%)。
- 维生素C与血管活性药支持时间和机械通气时间缩短相关,但不影响入科24小时内液体需求或尿量。
- 急性肾损伤例数、ICU住院时间和住院时间未受维生素C影响。
适用人群与场景
- 危重症成人患者,研究纳入静脉给予维生素C者,无论剂量或是否联用抗氧化剂。
处置流程与药物剂量
- 静脉维生素C 3-10 g/d与危重症患者死亡率降低相关(OR 0.25;95%CI 0.14-0.46;p<0.001;I²=0.0%)。
- 静脉维生素C <3 g/d对死亡率无效应(OR 1.44;95%CI 0.79-2.61;p=0.234;I²=0.0%)。
- 静脉维生素C ≥10 g/d对死亡率无效应(OR 1.12;95%CI 0.62-2.03;p=0.700;I²=0.0%)。
研究设计与关键结果
- 该荟萃分析共纳入1210例患者,主要终点为末次随访全因死亡率。
- 静脉维生素C 3-10 g/d降低危重症患者死亡率:OR 0.25(95%CI 0.14-0.46;p<0.001;I²=0.0%)。
- 低剂量(<3 g/d)对死亡率无效应:OR 1.44(95%CI 0.79-2.61;p=0.234;I²=0.0%)。
- 高剂量(≥10 g/d)对死亡率无效应:OR 1.12(95%CI 0.62-2.03;p=0.700;I²=0.0%)。
- 维生素C与血管活性药支持时间和机械通气时间缩短相关,但不影响入科24小时内液体需求或尿量。
- 急性肾损伤例数、ICU住院时间和住院时间未受维生素C影响。
证据类型、等级与局限
- 证据类型:荟萃分析。
- 作者指出鉴于原始文献的局限性,需进一步研究以完全明确维生素C在危重症患者管理中的有效性。
对床旁实践的改变
- 作者认为静脉维生素C可缩短血管活性药支持和机械通气时间,3-10 g维生素C降低总死亡率。
- 作者指出鉴于原始文献的局限性,需进一步研究以完全明确维生素C在危重症患者管理中的有效性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Low levels of ascorbic acid (AA) have been detected in critically ill patients in which AA supplementation leads to promising outcomes. However, the ability of AA to reduce mortality in critically ill patients remains controversial. In this study, we have performed a meta-analysis to evaluate the effects of AA dose on the mortality of critically ill adults.
METHODS: Electronic databases were searched for trials in which AA had been intravenously administered to critically ill patients regardless of the dose or the co-administration of antioxidant agents. The predefined primary outcome included all-cause mortality at final follow-up.
RESULTS: The included trials enrolled a total of 1210 patients. Intravenous (IV) AA doses of 3-10 g/d reduced the mortality of critically ill patients (OR 0.25; 95% CI (0.14-0.46); p < 0.001; I2 = 0.0%), while low (< 3 g/d) and high AA doses (≥ 10 g/d) had no effect (OR 1.44; 95% CI (0.79-2.61); p = 0.234; I2 = 0.0% versus OR 1.12; 95% CI (0.62-2.03); p = 0.700; I2 = 0.0%). AA was associated with a decreased duration of vasopressor support and mechanical ventilation, but did not influence fluid requirement or urine output during the first 24 h of admission. The number of patients suffering from acute kidney injury and the length of intensive care unit or hospital stays were also unaffected by the AA.
CONCLUSION: Intravenous AA reduces the duration of vasopressor support and mechanical ventilation; 3-10 g AA results in lower overall mortality rates. Given the limitations of the primary literature, further studies are required to fully clarify the effectiveness of AA during the management of critically ill patients.
参考来源
- Wang Y, Lin H, Lin BW, et al. Effects of different ascorbic acid doses on the mortality of critically ill patients: a meta-analysis. Ann Intensive Care. 2019. PMID: 31111241. doi:10.1186/s13613-019-0532-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。